Recently, TOMI Environmental Solutions Chairman and CEO spoke to the OTC Markets Group about TOMI in 2016 and where we’re headed in 2017, take a look at his interview below:
|“In 2017, we are poised to grow externally in our national and international markets, and broaden our investor base. TOMI plans on developing and changing the disinfection/decontamination industry standards forever as we believe we offer the world’s most comprehensive deployable disinfection/ decontamination solution. TOMI has robust potential and we look forward to bringing in more investors to further our potential growth.”
OTC Markets Group (OTCM): Tell us about TOMI.
Dr. Halden Shane: TOMI Environmental Solutions specializes in disinfection and decontamination solutions for companies whose facilities are at risk from infectious diseases. These facilities include hospitals, laboratories, and even schools. TOMI owns the technology and its related patents that was developed by DARPA and a U.S. defense company. TOMI sells and offers rapidly-deployable SteraMist™ Binary Ionization Technology® (BIT™) in both the United States and internationally with our SteraMist platform of products. TOMI also has custom build-in solutions of our SteraMist technology with our industry partners in containment, mitigation, and decontamination. Furthermore, the TOMI Service Network allows for our technology to be present in communities nationwide for routine and first responder service jobs. We are proud to offer solutions to disinfection/decontamination in the healthcare, pharmaceutical, laboratories, and commercial spaces.
OTCM: What were your major accomplishments in 2016?
Dr. Shane: In 2016, TOMI continued to work closely with our manufacturing partners to diversify our implementation in a variety of verticals, as well as evolving the capacity and applications of the SteraMist™ Binary Ionization Technology® (BIT™). In addressing our customers’ needs, TOMI has developed numerous new designs of our SteraMist equipment to fit into numerous areas/spaces.
During 2016, TOMI filed four new patent applications with the U.S. Patent and Trademark Office to protect TOMI’s groundbreaking SteraMist™ designs for decontamination and disinfection modules, chambers, carts, and other equipment.
TOMI is continuously developing custom fit build-in proposals for full rooms, pass-boxes, chambers, Bag-in/Bag-Out (BIBO), and other laboratory and bio-safety enclosures for our current and potential customers, as well as looking to invent new technologies to further our motto of “Innovating for a Safer World”.
TOMI continues to work closely with our licensed worldwide strategic customers and has supplied our technology to be developed for custom build-in applications for them. TOMI developed a rapid cycle decontamination unit in a custom enclosure for use by Type Solutions, SA, a laboratory and industrial equipment company located in Portugal. Similarly, TOMI technology is sold under license for customized build-in solutions for Telstar Group in Spain and AM Instruments Srl in Italy which the respective companies use within their pharmaceutical laboratory and cleanroom equipment which they manufacture. This provides their end users a decontamination/sterilization validation without damage to their clients’ delicate equipment and fixed materials. These developments all result in a much quicker treatment time than competitive fogging decontamination/sterilization solutions.
TOMI in 2016 saw an improvement in our TOMI Service Network, welcoming 36 new providers for a total network of 58 providers using SteraMist BIT in their communities. In addition, TOMI continued to expand our end user client base, adding almost 50 new customers and expanding our global presence in Asia, EU and many other countries.
And of course, in September 2016 TOMI upgraded and began trading on the OTCQX Best Market under the symbol “TOMZ. ”
OTCM: How does TOMI differentiate itself from its competitors and what is your growth strategy for 2017?
Dr. Shane: We differentiate from our competitors in the way that any technology would ideally differentiate from a competitor by being faster, more efficient, using less caustic materials and being more environmentally friendly.
In 2017, we are approaching our growth strategy through several different angles:
First, our Technology: We recently announced a continuation of our relationship with RG Group which has been our manufacturing partner for over two years now. We continue to work at improving our technology along with creating new applications platforms to implement our technology, which includes new ways to deliver disinfection/decontamination. This includes two prototypes which are currently in the works.
Our Innovation: Along with the prototypes which are currently being developed, we are continuing to test the efficacy of our BIT solution against harmful pathogens we find in the world’s communities. This testing has led us to apply for an amended EPA registration which will open doors for additional services in new verticals, including food safety. Furthermore, we will continue to seek new methods of using our technology. Along with internal innovation, in 2017 we are expecting several papers to reflect efficacy in several areas which will show the diversity of the SteraMist product in many respective fields.
Our Partnerships: Soon, TOMI will announce partnerships in the world of disinfection/decontamination with like-minded companies and further expansion of our TOMI Service Network and facilities which will incorporate TOMI’s SteraMist™ technology in their disinfection/decontamination plans.
OTCM: TOMI upgraded to OTCQX from the Pink market in September 2016. How are you planning to use OTCQX as part of your IR program?
Dr. Shane: In 2017, OTCQX will play a large role in our IR program as we look to the OTCQX Market for guidance in helping expand our investor base. We see OTCQX’s growth as our own. OTCQX attracts high-tech and forward-thinking investors, and TOMI sees its technology in line with such thinking. Coupled with the marketing, support and interactive nature of OTCQX, TOMI understands and appreciates all these as advantages to its relationship with OTCQX.
OTCM: What else do you want investors to know about TOMI?
Dr. Shane: 2016 saw lots of investment and internal growth at TOMI. In 2017, we are poised to grow externally in our national and international markets, and broaden our investor base. TOMI plans on developing and changing the disinfection/decontamination industry standards forever as we believe we offer the world’s most comprehensive deployable disinfection/ decontamination solution. TOMI has robust potential and we look forward to bringing in more investors to further our potential growth.
Thanks to the OTC Markets Group for their time, you can read their entire March Newsletter including the above interview HERE.